Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease

NCT07166757 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease (PD)

Interventions

DRUG: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

Sponsor

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.